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Abstract Human protein HC is a member of the lipocalin 
superfamily with unique properties since it carries a covalently 
bound fluorescent chromophore mediating the linkage of the 
major part of protein HC to several plasma proteins, with IgA as 
the dominating complex partner. Native protein HC displays 
characteristic absorption and fluorescence spectra similar to 
those of glycated proteins with advanced glycosylation end 
products (AGEs). In vitro glycation of protein HC induces the 
formation of fibril aggregates with a corresponding increase of 
absorption in the visible region of the spectrum. Boronate-
affinity chromatography and a novel galactosyltransferase assay 
indicate that protein HC is modified with residues of glucose 
exposed in a terminal non-reducing position which is typical of 
glycated proteins. The glycation level of several isolated batches 
of protein HC as measured by both assays was around 35%, 
which represents the highest level described for human plasma-
derived proteins from healthy individuals. 
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1. Introduction 
Protein HC (human complex-forming glycoprotein hetero-
geneous in charge) is a low molecular weight plasma protein 
that belongs to the lipocalin superfamily of hydrophobic lig-
and-binding proteins. It is unique among the large lipocalin 
family since its major brown fluorescence ligand displays ex-
tensive charge and size heterogeneity [1-6]. Its chromophore is 
covalently linked to the polypeptide chain by a novel non-
thioester reduction-resistant bond involving the cysteine resi-
due 34 [5] giving the protein its spectroscopic properties and 
its heterogeneity. A related reduction-resistant linkage has 
been reported in the HC-IgA complex with the chromophore 
acting as an intermolecular bridge linking cysteine 34 on pro-
tein HC to the penultimate cysteine residue in the carboxy-
terminal end of one of the IgA light chains [6]. Although the 
structure of the protein HC chromophore has not yet been 
elucidated, the chromophore displays characteristic absorp-
tion and fluorescence spectra [1-6] which are closely related 
to those of glycated proteins carrying advanced glycosylation 
end products (AGE) [7]. 
Corresponding author. Fax: (34) (1) 5854506. 
E-mail : emendez@cnb.uam.es 
lrrhe first two authors have contributed equally to this paper. 
Protein glycation involves the non-enzymatic covalent bind-
ing of glucose and other reducing monosaccharides to a- and 
ε-amino groups of polypeptide chains to yield Schiff-base in-
termediates which via Amadori rearrangement form more sta-
ble ketoamine derivatives. These derivatives may subsequently 
undergo slow and only partially characterized reactions to 
form heterogeneous fluorescent and non-fluorescent AGE. 
The formation of AGE affects mainly longlived proteins, 
e.g. collagen, laminin and fibronectin of the extracellular ma-
trix [8,9], although recently there have been an increasing 
number of reports concerning the presence of glycation in 
several non-longlived plasma proteins and tissue proteins as 
well [10-15]. The modified proteins usually develop inter- and 
intra-polypeptide chain linkages, become protease-resistant 
and detergent-insoluble and display characteristic fluorescence 
spectra [16]. The glycation and subsequent generation of AGE 
is believed to be pivotal in the normal human aging process 
and in the production of the abnormal protein deposits occur-
ring in the brains of Alzheimer patients [17,18]. The raised 
blood glucose level in diabetes causes an increased rate of 
glycation of proteins and is thus assumed to be involved in 
the pathogenesis of late diabetic complications. In healthy 
persons, the serum albumin and hemoglobin glycation levels 
are, expressed as percentage of glycated protein, below 1-6% 
[19] and 4-5% [20], respectively. In the present work we dem-
onstrate by boronate-affinity chromatography, and by a col-
orimetrie assay and a novel galactosyltransferase assay, that 
protein HC of non-diabetic individuals is glycated to more 
than 30%. 
2. Materials and methods 
2.1. Isolation of protein HC 
Protein HC was purified from the urine of non-diabetic patients as 
described earlier [1,2]. 
2.2. Boronate-affinity chromatography 
Glyco-Gel II from Pierce was used in affinity chromatography to 
separate and quantify glycated forms of native and deglycosylated 
protein HC (100 μg). Bound proteins were eluted with a buffer con-
taining sorbitol following the manufacturer's instructions. The relative 
ratios of bound and non-bound fractions (500 μΐ) were quantified by 
amino acid analysis of the pooled fractions. 
2.3. Galactosyltransferase assay 
The UDP-galactose: glycoprotein galactosyltransferase (EC 
2.4.1.38) was assayed essentially as described [18] using native and 
deglycosylated HC as an exogenous acceptor. The samples assayed 
were the pooled fractions (retained and non-retained) obtained from 
the Glyco-Gel II chromatography. 
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2.4. Colorimetrie glycation assay 
For the colorimetrie determination of protein HC glycation, a 
method recently developed by Kennedy and co workers [21] was car-
ried out with and without modifications (under borohydride reduc-
tion) using in vitro glycated fetuin as a standard in order to avoid 
interference due to the protein HC glycosylation. For the calibration 
curve, mixtures of in vitro glycated and non-glycated fetuin in varying 
proportions were prepared so that the total concentration of protein, 
and hence glycosylation interference, remained constant. The in vitro 
modified fetuin bound to the boronic acid column was considered to 
represent 100% glycated fetuin. 
2.5. Glycation of proteins in vitro 
Samples of fetal calf fetuin (5 mg/ml) and protein HC (1.0 mg/ml) 
were incubated with 500 mM glucose in 50 mM phosphate buffer, pH 
7.0, for 20 and 110 days, respectively, at 37°C. Alternatively, 50 μg of 
protein HC was incubated with 1 μ θ of D-[14C]glucose (56.4 mCi/ 
mmol) in 50 mM phosphate buffer for up to 16 days. 
2.6. High performance liquid chromatography (HPLC) 
Size-exclusion HPLC was performed in a Pharmacia Smart system 
using a Superdex 75 PC 3.2/3 micro-column (3.2X300 mm) connected 
on line with a Waters 996 Photodiode Array Detector. The column 
was equilibrated and eluted with 50 mM phosphate buffer, pH 7.0, at 
room temperature and at a flow rate of 0.04 ml/min. 
2.7. Enzymatic removal of glycans 
Treatment of protein HC with ß-JV-acetylhexosaminidase (Jack 
Bean, EC 3.2.1.30, Oxford Glycosystems, Oxford, UK), PNGase F 
(Flavobacterium meningosepticum, Oxford Glycosystems) and endo-cc-
7V-acetylgalactosaminidase (O-glycanase, Streptococcus pneumoniae, 
EC 3.2.1.97, Oxford Glycosystems) was carried out according to the 
manufacturer's instructions. 
2.8. Electron microscopy 
For electron microscopy, 5 μΐ of in vitro glycated and native HC (1 
μg/μl) was applied to Formvar-coated nickel grids, negatively stained 
with 2% (w/v) uranyl acetate, and observed in an electron microscope 
model 410 (Philips Electronic Instruments, Mahwah, NJ) at 80 kV. 
3. Results 
3.1. Boronate-affinity chromatography of protein HC 
Boronate-affinity chromatography is routinely used to assay 
glycated proteins since only those glycated proteins bind to 
and are retained by the matrix. Thus, five preparations of 
protein HC isolated from the urine of non-diabetic patients 
were tested for glycation by binding to a boronate-affinity 
chromatography column. Each preparation was applied to a 
2-ml Glyco-Gel column and the retained fractions of protein 
HC were eluted with sorbitol-containing buffer. The retained 
and non-retained fractions were quantified by amino acid 
analysis (using norleucine as internal standard) after hydrol-
Table 1 
Glycation analysis of protein HC by GlycoGel system and colori-
metrie assay 
Lot 
87 
88 
90 
91 
92 
% H C 
bound" 
32.4 
48.1 
25.3 
36.2 
34.3 
cpm [3H]Gal 
to HCb 
7 501 
8412 
12523 
11231 
10737 
linked % of [3H]Gal-HC 
boundc 
66.6 
72.3 
84.3 
76.2 
83.5 
a% of protein HC bound to the GlycoGel column. 
bRadioactivity associated with protein HC after labeling via the gal-
actosyltransferase assay. 
c% of protein HC bound to the GlycoGel after treatment with 
PNGase and ß-hexosaminidase followed by labeling via the galacto-
syltransferase assay. 
20 
TIME (min) 
Fig. 1. In vitro glycation of protein HC as revealed by the forma-
tion of aggregates. Incubation in 500 mM D-glucose took place for 
110 days. At the indicated times, the samples were centrifuged at 
14000 rpm for 3 min and the supernatant was subjected to size-ex-
clusion HPLC. The absorption spectra normalized to 280 nm, auto-
matically determined at the peak maxima of the monomeric peak, 
are shown above. The inset shows the electron microscopy image 
showing fibril aggregates stained with 2% uranyl acetate. The colori-
metrie glycation assay of protein HC using fetuin as a standard 
curve is also shown in an inset. Arrows show the OD values ob-
tained for the three samples of native and in vitro glycated protein 
HC at two different durations of glycation, 23 and 52 days. The 
percentage glycation is indicated in parentheses. 
ysis. Table 1 shows that all protein HC preparations contain a 
high proportion (25^18%) of molecules containing си-diol 
groups and hence are retained by the column and eluted by 
sorbitol as described to be characteristic for glycated proteins. 
Deglycosylated protein HC behaves on the phenylboronate 
column as native protein HC, suggesting that protein glyco-
sylation does not determine the binding of protein HC to the 
affinity resin (results not shown). 
3.2. Galactosyltransferase assay of protein HC 
A novel galactosyltransferase assay designed to demon-
strate the presence of free non-glycosylation (./V-, O-, or O-
GlcNAc) terminal residues of glucose and/or NAcGlc in pro-
teins by the transfer of [3H]galactose to such groups was ap-
plied to protein HC preparations. Table 1 demonstrates that 
all preparations of protein HC incorporate relevant amounts 
of radiolabeled galactose. As protein HC contains two N-gly-
cans per molecule, the protein HC preparations were treated 
with PNGase to completely remove the /V-glycans with puta-
tive terminal GlcNAc residues which could act as acceptors 
for [3H]galactose. This treatment reduced the protein HC-
linked [3H]galactose counts by less than 18% in all prepara-
tions, indicating that more than 80% of the incorporated 
[3H]galactose is in a non-glycosylation-derived residue. Fur-
thermore, pretreatment of the samples with ß-hexosaminidase 
to specifically remove terminal GlcNAc residues present in 
any glycan diminished the transfer of [3H]galactose to protein 
HC by the same magnitude as the PNGase pretreatment (less 
than 22%). This result points to a specific linkage of the 
[3H]galactose to other residues than those from N-glycans. 
In addition, treatment of the radiolabeled samples with 
endo-a-N-acetylgalactosaminidase (O-glycanase) had no effect 
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Fig. 2. Radioactivity profile of size-exclusion HPLC of protein HC 
glycosylation with D-[14C]glucose after 16 days. Time courses of to-
tal radioactivity (monomer, M and dimer, D) are shown in the in-
set. 
on the labeling efficiency, thus ruling out any possibility that 
the radioactive sugar is transferred to the 0-glycans. It is 
important to mention that the galactosyltransferase assay 
was done in the presence of lactalbumin so that the transfer 
of radiolabeled galactose is towards glucose residues and not 
to GlcNAc residues. 
The results of boronate-affinity chromatography and the 
galactosyltransferase assay clearly indicate that a large pro-
portion of the investigated protein HC populations are modi-
fied by glucose residues attached to protein molecules and 
exposed in a terminal non-reducing position. As an additional 
control to check that the components mediating the binding 
of protein HC to the boronate column are the same as those 
acting as acceptors for [3H]galactose residues, protein HC 
samples, previously deglycosylated and terminal GlcNAc re-
moved by treatment with PNGase and ß-hexosaminidase and 
then [3H]galactose-labeled, were tested by boronate-affinity 
chromatography. The results presented in Table 1 show that 
a large part of the radioactivity was retained by the column, 
hence providing further evidence supporting the notion that 
the presence of terminal non-glycosylation-derived glucose 
residues on protein HC molecules may cause their binding to 
boronate columns. It should be emphasized that [3H]galactose 
labeling of in vitro glycated native and deglycosylated bovine 
serum albumin, IgG, RNAse and ovalbumin does not signifi-
cantly affect the binding of those proteins to the boronate-
affinity chromatography (Bonay et al., manuscript in prepa-
ration). 
3.3. Colorimetrie assay of glycation 
During the course of this investigation we decided to test 
another assay of glycation, free of interference from other 
post-translational modifications like glycosylation [21], in or-
der to rule out the possibility that modifications other than 
glycation are responsible for the high binding values obtained 
in the boronic acid assay. This assay requires the reduction of 
the proteins with sodium borohydride prior to periodate ox-
idation, thus increasing the amount of formaldehyde released 
proportional to the glycation without interference from sugars 
in the glycosylated glycans. For the calibration curve we used 
in vitro glycated fetuin as a standard, since it is a moderately 
glycosylated protein, like protein HC. The results of applying 
this colorimetrie assay to protein HC are shown in Fig. 1, 
which clearly demonstrates that native protein HC is glycated 
since it gives a readout equivalent to a fetuin glycation level of 
18% (Table 1). Furthermore, as an internal validation of the 
method, in vitro glycated protein HC after two different in-
cubation periods (23 and 52 days) was also tested in the col-
orimetrie assay giving consistent and repeatable values of 
equivalent fetuin glycation of 22 and 41% respectively. Those 
values fit with the other parameters used to evaluate the in 
vitro glycation of protein HC and confirm the high basal 
glycation state of native protein HC. The same assay done 
with in vitro glycated bovine serum albumin as a standard 
protein provides similar values of glycation (results not 
shown). 
3.4. Incorporation of [^ С]glucose into protein HC 
Protein HC (0.34 mg/ml) was incubated with a low concen-
tration of [14C]glucose for various periods and then analyzed 
by size-exclusion HPLC. The virtually identical chromato-
grams obtained after incubation periods of 6 h and 16 days 
(Fig. 2) demonstrated that the two protein HC populations 
contained a predominant monomeric and a small dimeric 
fraction and displayed the same dimer/monomer ratio. How-
ever, while the short incubation period of 6 h led to incorpo-
ration of glucose only into the monomeric fraction, incuba-
tion periods of 6-16 days produced glucose incorporation also 
into the dimeric fraction, which contained about 60% of the 
glucose after the longer incubation periods (Fig. 2). The total 
amount of radiolabeled glucose incorporated increased with 
the incubation period and reached a plateau level after 6 days 
(Fig. 2, inset). 
3.5. Glucose-induced oligomerization of protein HC 
In a second incubation experiment, protein HC (1.0 mg/ml) 
was incubated with a high concentration of glucose (500 mM) 
and the mixture analyzed by gel chromatography after various 
periods of incubation up to 110 days. Fig. 1 shows a reduction 
in the light absorption of the protein HC solution as a con-
sequence of the characteristic formation of fibrils and amor-
phous aggregates typical of in vitro glycated proteins. The 
absorption spectra of each of the soluble in vitro glycated 
protein HC fractions, recorded at the peak maxima, were 
found to be similar, displaying significant absorption in the 
visible region like native protein HC, but with increased 330/ 
280 nm absorbance ratios. The absorbance ratio increased 
with the incubation period and reached a plateau level after 
approximately 50 days, much later than the equilibrium 
reached by the radiolabeled glucose incorporation, indicating 
the formation of post-Amadori products. 
4. Discussion 
The present work presents evidence indicating that protein 
HC is modified in such a way that glucose/glucosamine resi-
dues are exposed and accessible in a non-reducing terminal 
position characteristic non-exclusively of glycated proteins. 
The behavior of protein HC on boronic acid affinity chroma-
tography makes that modification compatible with glycation. 
In addition, protein HC is a good acceptor as revealed by a 
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recently described radiometrie assay developed to quantify 
glycation modified proteins [18]. To rule out any interference 
from other possible modifications, like N- or O-glycosylation, 
0-GlcNAc, which could artifactually affect the behavior of 
proteins on the affinity resin, we also tested the putative gly-
cation of protein HC by a colorimetrie assay claimed to be 
free of interference from glycosylation [21]. The results de-
rived from the three assays support the same conclusion 
that protein HC contains covalently linked and terminally 
exposed glucose residues other than those present on the O-
and iV-glycosylation sites already described in protein HC 
[22]. The most appropriate conclusion that can be derived 
from the evidence presented here and the analysis of post-
translational modifications of proteins found in the literature 
is the occurrence of glycation until further analysis is done. 
The apparent discrepancy in the levels of native protein HC 
glycation as determined by the affinity chromatography meth-
od (about 35%) and the colorimetrie assay (about 18%) can be 
easily explained since the latter value is a relative one based 
upon the glycation of a standard glycosylated protein like 
fetuin. In contrast, the affinity chromatography assay gives 
an estimation of the actual proportion of glycated protein 
HC molecules in the entire molecular population of protein 
HC. As the density of glucose residues on the polypeptide 
chain is known to affect the binding to the boronic acid resin, 
it could be stated that all protein HC is modified and only 
35% in such a degree as to be retained by the affinity resin. 
However, in spite of these differences between methods, what 
seems to be unique to protein HC is its degree of basal mod-
ification (glycation). Several plasma and tissue proteins in 
both healthy individuals and diabetic patients have been dem-
onstrated to be glycated and their glycation level shown to 
increase both with the blood glucose level and most probably 
also with the half-life of the protein. Interestingly, the re-
ported proportions of glycated proteins are not higher than 
20-22% in non-diabetic individuals and there is only one re-
port of a protein (Cu,Zn- Superoxide dismutase) with a gly-
cated fraction of 40% in diabetic patients [11]. The observed 
protein HC basal modification (glycation) level of over 30% is 
particularly interesting considering the short half-life and the 
source (urine) of the protein and since the investigated batches 
of protein HC were isolated from non-diabetic individuals. In 
addition to the basal modification identified on protein HC, 
we also report here that protein HC could be further modified 
in a saturable fashion by in vitro glycation, although to a 
minor degree, by the incorporation of radiolabeled glucose. 
Regarding the in vitro modification, it is noteworthy that it 
increases the browning of the modified protein above the lev-
els of the native protein HC, concomitant with the equivalent 
glycation values derived from the colorimetrie assay of glyca-
tion. 
The observed high level of modification (glycation) of na-
tive protein HC prompted studies on the interaction of glu-
cose and native protein HC. Incubation with low levels of 
[14C]glucose induced incorporation of glucose into monomeric 
protein HC within hours. A prolonged incubation period re-
sulted in increased glycation of protein HC, most of the gly-
cation occurring in the dimeric protein HC fraction. These 
results suggest that protein HC glycates easily and that glyca-
tion might be involved in the formation of protein HC dimers, 
some of which are known to form by bonds which are resist-
ant to reduction, as is the case for the bond between protein 
HC and IgA in the protein HC-IgA complex [2,4,6]. Incuba-
tion of protein HC with higher concentrations of glucose re-
sulted in precipitation of protein HC as aggregates and fibrils. 
Interestingly, the remaining still soluble fraction of protein 
HC displayed an absorption spectrum similar to that of native 
protein HC but with a noticeable increase in the absorption 
above 300 nm, characteristic of the native protein HC chro-
mophore. These results suggest that glycation might be in-
volved in the formation of the protein HC chromophore 
and, in addition, that glycation might be involved in the for-
mation of reduction-resistant links between protein HC and 
several other proteins since it has been described that the 
chromophore of native protein HC mediates such links [6]. 
The present investigation demonstrates that native protein 
HC is highly modified (glycated), that it can be further modi-
fied by glycation in vitro and that the in vitro glycation may 
result in the formation of chromophores similar to those 
present in native protein HC. The location of the modification 
(glycation) sites on the polypeptide chain of protein HC is 
presently being addressed and at least six different galactosyl-
transferase-labeled [3H]galactose-protein НС-derived peptides 
have already been located along the polypeptide chain of pro-
tein HC (manuscript in preparation). It might be of signifi-
cance that the chromophores of both native and in vitro gly-
cated protein HC display several properties similar to those 
described for the poorly characterized post-Amadori prod-
ucts. For instance, the absorption and fluorescence spectra 
of the protein HC chromophores are closely related to those 
described for AGE, in spite of the short half-life of protein 
HC. The protein HC chromophore has recently been shown 
to be involved in the linkage of protein HC to the protein 
partners found on natural complexes like HC-IgA in a reduc-
tion-resistant bond. This property resembles the crosslinking 
of glycated proteins mediated by the post-Amadori products. 
While generally the in vitro glycation may confer non-specific 
crosslinking properties to the modified protein, protein HC is 
highly specific regarding the protein partners crosslinked in 
the complexes where the chromophore acts as an intermolec-
ular bridge involving cysteine residues. Thiols had not previ-
ously been demonstrated to be targets of glycation by glucose, 
let alone the massive glycation reported here. Further inves-
tigations are required to identify the chemical nature of the 
glycation described in this report as well as the precise sites on 
the polypeptide chain where this modification occurs. 
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